Organization
TESARO, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
TESARO, Inc.
... winning FDA approval for its injectable version of chemo nausea med Varubi, Tesaro is having to reach out to doctors to update them with a ...
... WALTHAM, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has updated the ...
... to the investment community. Today we are offering reports on EDIT, ILMN, TSRO, and ECYT which can be accessed for free by signing up tohttp://www.wallstequities.com/registration. ...
... announced today the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical company, to develop novel multi-specific antibodies for up ...
... AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-0), ...
... ZUG, Switzerland - TESARO, Inc.(NASDAQ: TSRO), an oncology-focused biopharmaceutical company, announced today that ZEJULA (niraparib), an oral, ...
... also currently available for patients in the UK who have private insurance TESARO will continue to make ZEJULA available across Europe in 2018 ZUG, Switzerland, ...
... partially beating out other I-O and gene editing tech for column inches. RELATED:Tesaro jumps on PARP ovarian cancer data, as drug hailed a ‘breakthrough’ The ...
... of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Edison International (NYSE:EIX), Anthem, Inc. (NYSE:ANTM), TESARO, Inc. (NASDAQ:TSRO), Brunswick Corporation (NYSE:BC), and BroadSoft, Inc. (NASDAQ:BSFT), including updated fundamental summaries, ...
... in the U.S. WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that VARUBI® (rolapitant) IV, is ...
... WALTHAM, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming ...
... WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered ...
... and Co-founder, and Mary Lynne Hedley, PhD, President, COO and Co-founder, of TESARO, Inc. have been named Entrepreneur Of The Year® 2017 National Overall Award ...
... UK this December ZUG, Switzerland, Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that the European Commission ...
... WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie ...
... If you want a Stock Review on OPHT, PTCT, TRVN, or TSRO then come over tohttp://dailystocktracker.com/register/and sign up for your free customized report. Today's ...
... included revenue related to two milestones earned from the company's partnership with TESARO. The three and nine months ended September 30, 2016 included revenue of ...
... of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. ('TESARO') to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab ...
... AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-0), ...
... - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. ('TESARO') today announced a three-year integrated drug discovery collaboration to discover and ...
... MIAMI - OPKO Health, Inc. (NASDAQ: OPK) announces that its licensee, TESARO, Inc. (Nasdaq: TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI ...
... polysorbate 80. 'The approval of VARUBI IV represents a significant milestone for TESARO. The majority of NK-1 receptor antagonist doses are administered intravenously in the ...
... of cancer, today announced the signing of a collaborative agreement with TESARO, Inc. ("TESARO") to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab ...
... (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that its licensee, TESARO, Inc. (Nasdaq:TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI® (rolapitant) ...
... content of this announcement. ------------------------------------------------------------ * DISCOVERY AND DEVELOPMENT OF INHIBITORS AGAINST TESARO'S IMMUNO-ONCOLOGY TARGET UTILISING EVOTEC'S COMPREHENSIVE DISCOVERY AND DEVELOPMENT PLATFORM Hamburg, Germany, 26 ...
Want to see the full history on TESARO, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial